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Abstract
Background: Mainly because of the diversity of clinical presentations, diagnostic delays in lymphoma can be
excessive. The time spent in primary care before referral to the specialist may be relatively short compared with the
interval between hospital appointment and diagnosis. Although studies have examined the diagnostic intervals and
referral patterns of patients with lymphoma, the time to diagnosis of outpatient compared to inpatient settings and
the costs incurred are unknown.
Methods: We performed a retrospective study at two academic hospitals to evaluate the time to diagnosis and
associated costs of hospital-based outpatient diagnostic clinics or conventional hospitalization in four representative
lymphoma subtypes. The frequency, clinical and prognostic features of each lymphoma subtype and the activities
of the two settings were analyzed. The costs incurred during the evaluation were compared by microcosting
analysis.
Results: A total of 1779 patients diagnosed between 2006 and 2016 with classical Hodgkin, large B-cell, follicular,
and mature nodal peripheral T-cell lymphomas were identified. Clinically aggressive subtypes including large B-cell
and peripheral T-cell lymphomas were more commonly diagnosed in inpatients than in outpatients (39.1 vs 31.2%
and 18.9 vs 13.5%, respectively). For each lymphoma subtype, inpatients were older and more likely than
outpatients to have systemic symptoms, worse performance status, more advanced Ann Arbor stages, and high-risk
prognostic scores. The admission time for diagnosis (i.e. from admission to excisional biopsy) of inpatients was
significantly shorter than the time to diagnosis of outpatients (12.3 [3.3] vs 16.2 [2.7] days; P < .001). Microcosting
revealed a mean cost of €4039.56 (513.02) per inpatient and of €1408.48 (197.32) per outpatient, or a difference of
€2631.08 per patient.
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Conclusions: Although diagnosis of lymphoma was quicker with hospitalization, the outpatient approach seems to
be cost-effective and not detrimental. Despite the considerable savings with the latter approach, there may be
hospitalization-associated factors which may not be properly managed in an outpatient unit (e.g. aggressive
lymphomas with severe symptoms) and the cost analysis did not account for this potentially added value. While
outcomes were not analyzed in this study, the impact on patient outcome of an outpatient vs inpatient diagnostic
setting may represent a challenging future research.
Keywords: Lymphoma, Outpatient, Inpatient, Time to diagnosis, Diagnosis, Length of stay, Excisional biopsy, Fine-
needle aspiration cytology, Emergency departments, Primary care
Background
In the absence of pathological lumps, lymphomas may
pose a difficult diagnostic challenge. Patients presenting
with enlarged lymphadenopathy are straightforwardly
diagnosed. However, others present with systemic symp-
toms such as long-lasting fever and progressive weight
loss and a worsening performance status. And in the
middle of the spectrum are patients who complain of
nonspecific or subtle symptoms [1].
Studies investigating the mean duration of intervals on
the illness paths of patients with lymphomas have shown
that whereas the patient interval (i.e. from onset of
symptoms to first medical contact) constitutes the lon-
gest individual interval, the primary care (PC) interval
(i.e. time spent in PC before referral to the specialist) is
highly variable depending not only on the PC physician
experience but also on the broad range of presenting
symptoms [1, 2]. Because symptoms are often seen in
PC in association with other more common and less
serious conditions, patients are referred to a wide range
of specialists, with a few referred directly to the appro-
priate secondary specialist [3]. A case series study con-
ducted in patients aged > 25 years with newly diagnosed
lymphomas who were first seen in PC revealed that only
12% were directly referred to the hematologist and that
this specialist reached a quicker diagnosis than any other
specialist [3]. Indeed, diagnostic delays can be excessive,
and studies have shown that the PC interval may be
relatively short compared with the diagnostic interval
(i.e. from first specialist appointment to actual diagnosis)
[2]. The heterogeneity of presentations and symptoms
severity reflects the heterogeneous assortment of lymph-
oma subtypes and their aggressive or more indolent
behavior [1, 2, 4, 5].
In the 2000 recommendations of the United Kingdom
(UK) to improve cancer survival, hematological malig-
nancies were considered as a single entity [6]. When
considering referral for specialist assessment, the up-
dated 2015 referral guidelines of the National Institute
for Health and Care Excellence (NICE) highlighted un-
explained lymphadenopathy and/or splenomegaly as well
as other symptoms and signs that may suggest Hodgkin
and non-Hodgkin lymphoma and that deserve further
investigation [7]. The updated guidelines included separ-
ate recommendations for adults and for children and
young people (aged 16-24 years) to indicate that there
are different referral pathways. However, the significance
and ranking of each particular sign and symptom is not
disclosed [7]. Although quick access lymph node diagnos-
tic clinics recommended by NICE in 2003 to reduce the
time to diagnosis in patients with suspected lymphoma [8]
appeared a more useful, simplified referral pathway [9],
the challenge of appropriate referral remains in those
patients who do not present with lymphadenopathy.
Many of the above findings come from the UK. How-
ever, they may well be generalizable to other health care
systems where the patient first sees a PC physician [10]
such as the Spanish public health care system.
To reduce diagnostic delays of patients with poten-
tially serious diseases, the Spanish health care system
created in the mid-2000s the so-called quick diagnosis
units (QDUs). These hospital based-outpatient facilities
have proven to be cost-effective alternatives to conven-
tional hospitalization for diagnostic workup of disorders
such as highly suspected cancer, severe anemia, or fever
of unknown origin [11–13].
Largely because of long-delayed investigations or-
dered by PC physicians, these patients were tradition-
ally hospitalized to speed-up the diagnostic process.
However, most of them were too well to justify admis-
sion as just waited for examinations without receiving
actual therapy [14–16]. While many QDUs were imple-
mented during the recent economic regression to re-
duce the huge expenses associated with hospitalization
[17–19], admission for workup is one of the most com-
mon reasons for inappropriate hospitalizations in Spain
and elsewhere [19–23].
In contrast to the more focused approach of specialists
at units such as the UK one-stop diagnostic clinics [9, 24],
the versatility of general internists for the diagnosis of
conditions characterized by nonspecific symptoms such as
unintentional weight loss, fatigue or unexplained fever
explains why QDUs are predominantly run by these
physicians [11–13, 25].
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Although reported data on these units are limited,
several advantages over hospitalization have been estab-
lished: in addition to ensuring a time to diagnosis similar
to the length of stay for the same evaluable conditions,
they are known to decrease emergency department (ED)
referrals from PC easing ED overcrowding, are associ-
ated with higher patient satisfaction scores, and are
considerably cost-saving [11–13, 15, 16, 25–29]. Yet to
be evaluated, patients’ physical performance should
allow them to travel from home to hospital and back for
visits and investigations.
Because an acceptable performance status argues in
general against admission of subjects who are eventually
diagnosed with lymphoma after referral to QDUs for in-
vestigation of typical or nontypical manifestations, these
outpatient units appear a proper setting for their assess-
ment. However, no study has examined the time to diag-
nosis and associated costs of an outpatient compared to
an inpatient setting. The main purpose of this retro-
spective study was to investigate the time to diagnosis of
a hospital-based outpatient or inpatient setting in four
major subtypes of lymphomas and the costs incurred by
both clinical settings in the diagnostic process. A further
goal was to investigate the frequency, clinical, and prog-
nostic features of each lymphoma subtype according to
an outpatient or inpatient diagnosis.
Methods
Settings and study population
The QDU of the Hospital Clínic (QDU (1)), a public
855-bed tertiary university hospital in Barcelona (Spain)
with a reference population of almost 550,000, the in-
patient wards of the internal medicine department of
this hospital, and the QDU of the Hospital of Bellvitge
(QDU (2)), a public 750-bed tertiary university hospital
near Barcelona with a reference population of almost
350,000, participated in the study. All patients had been
referred to the three settings from the respective PCs
and EDs between January 2006 and September 2016.
The referral criteria of the two outpatient units are
essentially the same [14, 15, 30]. For the purpose of this
study, both outpatient units were combined, and the
analyzed patients were considered a single outpatient co-
hort (herein referred to as ‘outpatients’). The study was
approved by the Comitè d’ Ètica de la Investigació
Clínica (Clinical Research Ethics Committee) of the
Hospital Clínic and the Comitè d’ Ètica i Assajos Clínics
(Ethics and Clinical Assays Committee) of the University
Hospital of Bellvitge. The ethics committees waived the
need for written informed consent because no interven-
tion was involved and the retrospective analysis of
clinical data.
To analyze a homogeneous and representative sam-
ple of major lymphoma subtypes, cases included were
patients aged ≥ 18 years with classical Hodgkin lymph-
oma, large B-cell lymphoma, follicular lymphoma, and
mature nodal peripheral T-cell lymphoma (comprising
peripheral T-cell lymphoma, not otherwise specified
[NOS], angioimmunoblastic T-cell lymphoma, and ana-
plastic large cell lymphoma, anaplastic lymphoma kinase
[ALK]-negative). All cases were diagnosed according to
the 2008 World Health Organization classification of
lymphoid neoplasms [31] and codified according to the
International Classification of Diseases for Oncology (3rd
edition; ICD-O-3) [32].
Pathologists at the Hospital Clínic and Hospital of
Bellvitge selected and reviewed histopathological data of
consecutive cases with these diagnoses, and attending and
resident physicians from the outpatient and inpatient
units reviewed the medical records of all patients and
entered the following data into an electronic database: 1)
individual frequency of lymphoma subtypes; 2) general
demographic and clinical information including clinical
manifestations at presentation (lymphadenopathy, sys-
temic, pain and chest symptoms, or other symptoms or
signs), relevant laboratory data (white blood cell count
[including absolute lymphocyte count], erythrocyte count,
platelet count, hemoglobin level, serum liver enzymes and
lactate dehydrogenase [LDH], serum albumin, erythrocyte
sedimentation rate, and C-reactive protein), and imaging
reports; and 3) specific lymphoma information including
Ann Arbor stage, Eastern Cooperative Oncology Group
(ECOG) performance score, B symptoms, extranodal dis-
ease, bulky disease (maximum tumor dimension ≥ 10 cm)
for classical Hodgkin and large B-cell lymphomas, inter-
national prognostic score (IPS) for advanced-stage clas-
sical Hodgkin lymphoma [33], international prognostic
index (IPI) score for large B-cell and nodal peripheral T-
cell lymphomas [34], follicular lymphoma international
prognostic index (FLIPI) score for follicular lymphoma
[35], and histologic grading of follicular lymphoma. The
medical records of patients without explicit registered in-
formation on ECOG performance, bulky disease, and IPS,
IPI, and FLIPI scores were carefully assessed to determine
these parameters when all individual required data were
available. Otherwise, the actual number and percentage of
cases relative to the total number of cases with complete
data for each parameter was entered into the database.
Patients without a biopsy-proven diagnosis and those
with human immunodeficiency virus infection, a prior
diagnosis of another lymphoma, incomplete clinical or
pathological information, lost to follow-up, or dead before
initial staging were excluded.
Fine-needle aspiration cytology
Although all study patients underwent an excisional
biopsy, we calculated in a separate analysis the number
of fine-needle aspiration cytologies (FNACs) performed
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and the proportion of suspected or compatible diagnosis
of lymphoma according to cytomorphology and/or flow
cytometry studies. In particular, following a systematic
approach [36], a fast FNAC was commonly performed in
patients (principally outpatients) with easily accessible
lumps, then followed by a mandatory excisional biopsy
in those with a suspicious/compatible lymphoma diag-
nosis. While both FNAC and biopsy were ordered by
physicians from the inpatient and outpatient settings, to
save time, outpatients with a positive FNAC result were
immediately referred to the hematology (for QDU (1))
and the oncology (for QDU (2)) outpatient clinics, without
need to wait for the biopsy being performed at time of
referral. In contrast, irrespective of FNAC, all inpatients
were discharged once the biopsy had been performed and
its results were available. For consistency, cytologists at
the two hospitals reviewed cytologic data of patients with
a positive FNAC result and compared the cytologic and
histopathological findings on an individual basis.
Activities of the inpatient and outpatient settings
The activities of the inpatient and outpatient units during
the diagnostic evaluation were reviewed and registered.
These included intervals between referral and first out-
patient appointments/inpatient admissions, intervals be-
tween first outpatient appointments/inpatient admissions
and dates of FNACs and excisional biopsies, successive/
first visit ratio and time to diagnosis in outpatients,
length of stay in inpatients, and onward referrals upon
discharge of outpatients and inpatients. Additionally,
although disease staging was systematically performed
by the hematologist or the oncologist, physicians from
the inpatient and outpatient units ordered a positron
emission tomography-computed tomography (PET-CT)
scan when lymphoma was suspected or confirmed.
QDU time for diagnosis and admission time for diagnosis
As mentioned, outpatients with a positive FNAC diagno-
sis were discharged from the outpatient environment
without an excisional biopsy still being done. To allow
for a better meaning and equivalent measure of time to
diagnosis between outpatients and inpatients, we defined
QDU time for diagnosis as the time elapsed between the
first outpatient visit and the excisional/diagnostic biopsy,
and admission time for diagnosis (instead of length of
stay) as the actual time elapsed between inpatient admis-
sion and the excisional biopsy. This was made to try to
deal with the differences in patient- and lymphoma-
related characteristics that may influence comparison
between results. More specifically, because the duration
of hospitalization is likely impacted by inpatient factors
(i.e. inpatients may be older, sicker, and have presented
with more symptoms and advanced stages of disease
than outpatients), length of stay may not be a precise
reflection of the time needed to evaluate and diagnose a
patient with lymphoma. Indeed, inpatients may require a
longer hospitalization both to expedite lymphoma diag-
nosis and for symptom management and, as such, they
are more prone than outpatients to incur greater care-
related costs.
Resource use data collection and cost analysis
Costs of outpatients and inpatients were analyzed and
compared with the microcosting method, often consid-
ered as a paradigm of hospital service costs, since all rele-
vant cost components are precisely determined [37–39].
The microcosting methodology used by us for other disor-
ders has been described elsewhere [11–13, 27]. In brief,
resource use for each patient evaluated was obtained.
Resource use data collected included all laboratory tests,
cytologies, biopsies, imaging studies, and any other diag-
nostic procedure performed. The excisional biopsy re-
quested for outpatients who were discharged with an
onward referral if the FNAC result was positive was also
included in the cost analysis. Data were also gathered
on pharmaceuticals and consumables, therapeutic pro-
cedures, adverse events, and consultations. Only treat-
ments other than lymphoma-specific treatments (i.e.
treatment of patient’s symptoms) were included in the
analysis. Thus, lymphoma-specific therapies such as
chemotherapy and biologic agents were started by the
hematologist or the oncologist after their first patient
assessment once inpatients and outpatients had been
discharged and referred to them. Costs of all individ-
ual resource items of outpatients and inpatients were
obtained from the institutional information systems of
the Hospital Clínic and Hospital of Bellvitge (bottom-
up microcosting). For outpatients, the cost of an aver-
age outpatient consultation was determined according
to officially established Catalan Health Service fees. In
addition, the cost of each type of diagnostic investigation
corresponded to hospital tariffs for QDU (1) outpatients
and Catalan Health Service fees for QDU (2) outpatients.
For inpatients, the costs of diagnostic tests, which were
based on the same costs used for QDU (1) outpatients,
were also computed.
The microcosting analysis also incorporated fractions of
all staff wages. Particularly, QDU (1) is integrated in the
internal medicine department of the Hospital Clínic and
its staff includes a full-time consultant internist, a senior
internal medicine resident, a full-time nurse, a part-time
nurse coordinator, and two part-time secretaries. The unit
is open 5 h a day, 4 days a week. Furthermore, QDU (2) is
also integrated in the internal medicine department of the
Hospital of Bellvitge and its staff includes a part-time con-
sultant internist and a part-time nurse. This unit is open
7 h a day, 2 days a week. Finally, staff in the inpatient
setting (three wards) includes two full-time consultant
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internists, three residents, a full-time nurse coordinator,
three teams of three full-time nurses and three teams of
two full-time nursing assistants (8-h daily shifts), and a
full-time secretary.
With an outpatient approach, patients (and any care-
giver) may incur in more costs. Thus, indirect costs and
costs borne by patients were not included in the cost
analysis. Depreciation of fixed costs was included in the
final analysis.
Mean number of visits, cost per visit and cost per pa-
tient from QDU (1) and (2), and mean admission time
for diagnosis, cost per day of stay and cost per patient
from the inpatient wards were computed and compared.
Costs of referring agencies were excluded. All costs were
adjusted for the year of collection (2006-2016) to reflect
2016 Euros (€). Final costs and cost differences are
presented in 2016 Euros.
Statistical analysis
Categorical data were compared using the chi-square test
or the Fisher’s exact test, as appropriate, and are expressed
as absolute frequencies (%). Continuous variables with a
normal distribution were compared using the t-test, and
are expressed as means with standard deviations (SD).
The nonparametric Mann-Whitney U test was used, when
appropriate, to compare continuous variables with skewed
distributions. The extent and nature of any missing data
was also included in the analysis. Statistical significance
was set at P < .05. Analyses were performed using the
SPSS software (version 21.0) (SPSS, Chicago, USA).
Results
General characteristics of study population
Of 2047 eligible patients, 328 were excluded. Figure 1
shows the number of initially eligible patients from
QDU (1), QDU (2), and inpatient wards and the causes
for their exclusion. The main reasons for exclusion were
incomplete clinical or pathological information and
absence of a conclusive pathological diagnosis. After ex-
clusion, 1719 patients comprising 1184 outpatients (688
from QDU (1) and 496 from QDU (2)) and 535 inpa-
tients were available for the analysis (Fig. 1). The general
characteristics of the whole population is shown in
Table 1. Mean age was 63.4 (17.4) years and 55.4% were
Fig. 1 Flowchart of patients included in the study. Abbreviations: QDU (1) cohort of patients from the quick diagnosis unit of the Hospital Clínic,
QDU (2) cohort of patients from the quick diagnosis unit of the Hospital of Bellvitge, QDU (1) and (2) combined cohort of patients from the quick
diagnosis units of the Hospital Clínic and the Hospital of Bellvitge, Bx biopsy, Dx diagnosis, HIV human immunodeficiency virus, cHL classical
Hodgkin lymphoma, LBCL large B-cell lymphoma, FL follicular lymphoma, TCL mature nodal peripheral T-cell lymphoma
Bosch et al. BMC Cancer  (2018) 18:276 Page 5 of 15
males. There were minor differences in patient charac-
teristics between QDU (1) and QDU (2) outpatient co-
horts (Tables 1 and 2). Inpatients were older and more
likely to be males than outpatients. Nearly 65% of pa-
tients presented with lymphadenopathy, which was more
frequent in outpatients than in inpatients. Just above
25% of patients had systemic symptoms and these were
more common in inpatients (35.7%) than in outpatients
(21.8%). The main referral source of inpatients was ED
(i.e. emergency admissions) (68.4%) and it was PCs in
outpatients (75.5%). Expectedly, inpatients waited less
than 24 h to be admitted, whereas time to first visit in
outpatients was significantly longer (0.6 [0.3] vs 1.7 [1.1)
days; P < .001) (Table 1). The admission time for diagnosis
of inpatients was significantly shorter than the QDU time
for diagnosis of outpatients (12.3 [3.3] vs 16.2 [2.7] days;
P < .001). An FNAC was performed in 935 (54.4%) pa-
tients (766 [64.7%] outpatients and 169 [31.6%] inpatients)
yielding an overall suspicious/compatible lymphoma diag-
nosis in 65.3% with no false positive result in any patient
after considering the biopsy findings. The rate of positive
FNAC results was slightly, albeit nonsignificantly, higher
in outpatients than in inpatients. Specifically, 65.7% of
outpatients vs 63.9% of inpatients had a suspected/
compatible lymphoma by FNAC (P = .102). The mean
time to biopsy was substantially longer in outpatients
Table 1 General characteristics of study patientsa






IPs 2 (n = 535) P value 1 vs 2
Age (years), mean (SD) 63.4 (17.4) 62.7 (13.8) 61.8 (11.5) 62.3 (14.7) 65.6 (12.2) <.001
Sex, n (%)
Females 768 (44.6) 318 (46.2) 227 (45.8) 545 (46.0) 223 (41.7) <.001
Males 951 (55.4) 370 (53.8) 269 (54.2) 639 (54.0) 312 (58.3) <.001
Clinical manifestations, n (%)b
Lymphadenopathy 1112 (64.7) 487 (70.8) 358 (72.2) 845 (71.4) 267 (49.9) <.001
Systemic symptomsc 449 (26.1) 155 (22.5) 103 (20.8) 258 (21.8) 191 (35.7) <.001
Pain symptomsd 89 (5.2) 26 (3.8) 17 (3.4) 43 (3.6) 46 (8.6) <.001
Chest symptomse 45 (2.6) 14 (2.0) 12 (2.4) 26 (2.2) 19 (3.6) .128
Other symptoms/signsf 24 (1.4) 6 (0.9) 6 (1.2) 12 (1.0) 12 (2.2) .139
Referral sources, n (%)
Emergency department 656 (38.2) 182 (26.5) 108 (21.8) 290 (24.5) 366 (68.4) <.001
Primary care 1063 (61.8) 506 (73.5) 388 (78.2) 894 (75.5) 169 (31.6) <.001
Waiting time to first QDU visit/
admission (days), mean (SD)g
1.7 (0.8) 1.8 (0.7) 1.7 (1.1) 0.6 (0.3) <.001
Successive/first visit ratio 2.29 2.12 2.22
QDU time for diagnosis/admission
time for diagnosis (days), mean (SD)h
16.8 (2.5) 15.4 (2.2) 16.2 (2.7) 12.3 (3.3) <.001
Suspected/compatible lymphoma
by FNAC, n (%)/total ni
611 (65.3)/935 302 (67.3)/449 201 (63.4)/317 503 (65.7)/766 108 (63.9)/169 .102
Time to FNAC (days), mean (SD)j 1.2 (0.9) 1.5 (0.8) 1.0 (0.5) 1.3 (0.9) 1.2 (0.6) .183
Time to excisional biopsy (days),
mean (SD)k
5.7 (1.7) 7.5 (1.6) 7.1 (1.4) 7.4 (1.8) 3.5 (1.1) <.001
Onward referrals, n (%)
Outpatient specialist clinics 1622 (94.4) 654 (95.1) 476 (96.0) 1130 (95.4) 492 (92.0) .046
Primary care 47 (2.7) 21 (3.1) 15 (3.0) 36 (3.0) 11 (2.1) .169
Palliative care 50 (2.9) 13 (1.9) 5 (1.0) 18 (1.5) 32 (6.0) <.001
Abbreviations: QDU (1) OPs cohort of outpatients from the quick diagnosis unit of the Hospital Clínic; QDU (2) OPs cohort of outpatients from the quick diagnosis
unit of the Hospital of Bellvitge; Total OPs total number of outpatients from the quick diagnosis units of the Hospital Clínic and the Hospital of Bellvitge; IPs cohort
of hospitalized patients of the Hospital Clínic; FNAC fine-needle aspiration cytology
aLymphoma subtypes are not included; bSingle or combined; cMainly include intense tiredness, abnormal sweating at night, unintentional weight loss, nausea,
and anorexia; dMainly abdominal pain; eMainly include shortness of breath, cough, and sore throat; fInclude, among others, pruritus, bowel symptoms, unusually
thirsty, fever, and incidental findings on imaging studies; gIntervals between referral and first QDU appointment and hospital admission, respectively; hIntervals
between first QDU visit/hospital admission and excisional biopsies; in (%)/total n: actual number and percentage of cases relative to the total number of available
cases; jInterval between ordering FNAC and the procedure being done; kInterval between ordering biopsy and the procedure being done Missing data: variables
‘waiting time to first QDU visit’ (total OPs = 19), ‘waiting time to admission’ (IPs = 10), ‘time to FNAC’ (total OPs = 24, IPs = 16), ‘time to excisional biopsy’ (total
OPs = 6, IPs = 4)
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(7.4 [1.8] days) than in inpatients (3.5 [1.1] days)
(P < .001). After diagnosis, most patients were re-
ferred to outpatient specialist clinics and inpatients
more often received direct palliative care after dis-
charge than outpatients. There was ≤ 3% of missing
data on the variables waiting time to first QDU visit,
waiting time to admission, time to FNAC, and time
to excisional biopsy (see footnote of Table 1).
Frequency of lymphoma subtypes in outpatient and
inpatient settings
Table 2 shows the total number of lymphoma subtypes
and their frequency in each cohort of patients. Overall,
large B-cell lymphoma was the leading subtype of
lymphoma (33.6%) and follicular lymphoma ensued
(32.7%). Large B-cell lymphoma was more frequent in
inpatients than in outpatients (39.1% vs 31.2%; P < .001).
In contrast, follicular lymphoma was less common in
inpatients than in outpatients (23% vs 37.1%; P < .001).
Classical Hodgkin lymphoma made up 18.5% of lymph-
omas, without differences in its frequency between co-
horts. Nodal peripheral T-cell lymphomas were diagnosed
in 15.2% of patients, and were more prevalent in inpa-
tients than in outpatients (18.9% vs 13.5%; P < .001).
Peripheral T-cell lymphoma, NOS, was the main subtype
of nodal peripheral T-cell lymphomas (56.3%) and it was
more frequent in inpatients than in outpatients (59.4% vs
54.4%; P < .001). No differences were observed in the
frequency of angioimmunoblastic T-cell lymphoma and
anaplastic large cell lymphoma, ALK-negative, between
cohorts (Table 2).
Characteristics of lymphoma subtypes in outpatient and
inpatient settings
The characteristics of each subtype of lymphoma in
inpatients and outpatients are shown in Tables 3 and 4.
In all lymphoma subtypes, inpatients were significantly
older than outpatients. Also in all subtypes, lymphaden-
opathy was less common in inpatients than in outpa-
tients. Although systemic symptoms were more frequent
in inpatients than in outpatients, differences did not
reach significance in follicular lymphoma. Remarkably,
systemic symptoms were the leading clinical manifestation
in inpatients with nodal peripheral T-cell lymphoma
(46.5%), surpassing lymphadenopathy (38.6%) (Table 4).
Furthermore, pain symptoms were more common in inpa-
tients than in outpatients with large B-cell, follicular, and
nodal peripheral T-cell lymphomas. In all lymphoma
subtypes, the QDU time for diagnosis of outpatients was
significantly longer than the admission time for diagnosis
of inpatients as it was the time to biopsy of the former
compared to the latter (Tables 3 and 4). In addition, inpa-
tients with all subtypes of lymphoma were more likely
than outpatients to have a worse performance status, a
III-IV Ann Arbor stage, and B symptoms. Whereas an in-
creased LDH was more frequently observed in inpatients
than in outpatients with large B-cell, follicular, and nodal
peripheral T-cell lymphomas, bulky disease was more
common in inpatients than in outpatients with classical
Hodgkin and large B-cell lymphomas. Although extrano-
dal disease was more likely in inpatients than in outpa-
tients with all lymphoma subtypes, differences were only
statistically significant in large B-cell and nodal peripheral
T-cell lymphomas. Inpatients with all subtypes were also
Table 2 Frequency of lymphoma subtypes in outpatient and inpatient cohorts






IPs 2 (n = 535) P value 1 vs 2
Classical Hodgkin lymphoma 318 (18.5) 128 (18.6) 88 (17.7) 216 (18.2) 102 (19.1) .164
Nodular sclerosis, NOSb 235 (73.9) 96 (75.0) 66 (75.0) 162 (75.0) 73 (71.6) .045
Mixed cellularity, NOSc 37 (11.6) 16 (12.5) 10 (11.4) 26 (12.0) 11 (10.8) .135
Lymphocyte richd 13 (4.1) 5 (3.9) 3 (3.4) 8 (3.7) 5 (4.9) .140
Lymphocyte depletion, NOSe 4 (1.3) 1 (0.8) 0 (0.0) 1 (0.5) 3 (2.9) .078
Classical Hodgkin lymphoma, NOSf 29 (9.1) 10 (7.8) 9 (10.2) 19 (8.8) 10 (9.8) .156
Large B-cell lymphomag 578 (33.6) 218 (31.7) 151 (30.4) 369 (31.2) 209 (39.1) <.001
Follicular lymphoma, NOSh 562 (32.7) 250 (36.3) 189 (38.1) 439 (37.1) 123 (23.0) <.001
Mature nodal peripheral T-cell lymphomai 261 (15.2) 92 (13.4) 68 (13.7) 160 (13.5) 101 (18.9) <.001
Peripheral T-cell lymphoma, NOSj 147 (56.3) 50 (54.3) 37 (54.4) 87 (54.4) 60 (59.4) <.001
Angioimmunoblastic T-cell lymphomak 77 (29.5) 28 (30.4) 21 (30.9) 49 (30.6) 28 (27.7) .076
Anaplastic large cell lymphoma, ALK-negativel 37 (14.2) 14 (15.2) 10 (14.7) 24 (15.0) 13 (12.9) .086
Abbreviations: NOS not otherwise specified; ALK anaplastic lymphoma kinase. For other abbreviations, see Table 1
aThe ICD-O-3 codes of the International Classification of Diseases for Oncology, 3rd edition [32], are shown for each lymphoma subtype; b9663/3; c9652/3; d9651/3;
e9653/3; f9650/3; g9680/3, 9684/3, 9735/3, 9688/3, and 9679/3 (anaplastic large B-cell lymphoma, diffuse large B-cell lymphoma associated with chronic inflammation,
primary diffuse large B-cell lymphoma of the CNS, primary cutaneous DLBCL leg type, and EBV positive diffuse large B-cell lymphoma of the elderly were excluded);
h9690/3; i9702/3; j9702/3; k9705/3; l9702/3
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Table 3 Characteristics of classical Hodgkin and large B-cell lymphomas in outpatient and inpatient cohorts
Classical Hodgkin lymphoma (N = 318) Large B-cell lymphoma (N = 578)
Characteristic OPs 1 (n = 216) IPs 2 (n = 102) P value 1 vs 2 OPs 1 (n = 369) IPs 2 (n = 209) P value 1 vs 2
Age (years), mean (SD) 43.6 (15.8) 51.7 (13.3) <.001 65.1 (17.5) 69.7 (15.5) <.001
< 45, n (%) 113 (52.3) 44 (43.1) <.001
≥ 45, n (%) 103 (47.7) 58 (56.9) <.001
≤ 60, n (%) 121 (32.8) 28 (13.4) <.001
> 60, n (%) 248 (67.2) 181 (86.6) <.001
Sex, n (%)
Females 98 (45.4) 42 (41.2) .069 156 (42.3) 84 (40.2) .104
Males 118 (54.6) 60 (58.8) .074 213 (57.7) 125 (59.8) .091
Clinical manifestations, n (%)
Lymphadenopathy 152 (70.4) 51 (50.0) <.001 246 (66.7) 95 (45.5) <.001
Systemic symptoms 51 (23.6) 39 (38.2) <.001 101 (27.4) 86 (41.1) <.001
Pain symptoms 9 (4.2) 8 (7.8) .084 11 (3.0) 16 (7.7) .025
Chest symptoms 3 (1.4) 2 (2.0) .190 8 (2.2) 8 (3.8) .120
Other symptoms/signs 1 (0.0) 2 (2.0) .131 3 (0.8) 4 (1.9) .135
Successive/first visit ratio 2.10 2.33
QDU time for diagnosis /admission time for
diagnosis (days), mean (SD)
15.5 (1.7) 11.3 (2.7) .030 16.7 (2.2) 13 (2.5) .001
Suspected/compatible lymphoma by
FNAC, n (%)/total n
72 (52.9) /136 21 (52.5)/40 .203 156 (71.9)/217 35 (71.4)/49 .155
Time to FNAC (days), mean (SD) 1.3 (0.6) 1.1 (0.4) .130 1.3 (0.7) 1.2 (0.5) .125
Time to excisional biopsy (days), mean (SD) 7.3 (1.3) 3.3 (0.9) <.001 7.1 (1.3) 3.6 (0.9) .003
ECOG performance score > 1, n (%)/total n 31 (15.6)/199 21 (21.2)/99 .045 70 (20.8)/336 53 (27.5)/193 <.001
B symptoms, n (%)a 68 (31.4) 39 (38.2) .002 107 (29.0) 71 (34.0) .021
Serum LDH > UNL, n (%) 30 (13.9) 18 (17.6) .082 184 (49.9) 119 (56.9) <.001
Bulky disease, n (%)/total nb 44 (22.4)/196 27 (28.7)/94 .010 86 (24.9)/345 63 (31.5)/200 .001
Extranodal disease, n (%)c 33 (15.3) 20 (19.6) .061
> 1 extranodal site, n (%) 99 (26.8) 69 (33.0) .009
Ann Arbor stage, n (%)
I-II 142 (65.7) 60 (58.8) .002 157 (42.5) 71 (34.0) <.001
III-IV 74 (34.3) 42 (41.2) .001 212 (57.5) 138 (66.0) <.001
IPS score (advanced-stage diseasedd), n (%)/total n
Low risk (≤ 3) 166 (84.7)/196 74 (78.7)/94 .035
High risk (≥ 4) 30 (15.3)/196 20 (21.3)/94 .042
IPI score, n (%)/total n
Low risk (0-1) 114 (33.9)/336 52 (26.9)/193 <.001
Intermediate risk (2-3) 158 (47.0)/336 92 (47.7)/193 .144
High risk (4-5) 64 (19.0)/336 49 (25.4)/193 .004
Abbreviations: OPs total number of outpatients from the quick diagnosis units of the Hospital Clínic and the Hospital of Bellvitge; ECOG Eastern Cooperative
Oncology Group; LDH lactate dehydrogenase; UNL upper normal limit; IPS international prognostic score; IPI international prognostic index. For other
abbreviations, see Table 1
aRecurrent fever, night sweats, or > 10% weight loss; b ≥ 10 cm largest diameter; cInvolvement of extra lymphatic tissue; dAdvanced-stage disease was defined as
stage III or IV disease or stage I or II with bulky disease or stage II disease with B symptoms [59]
For other definitions and explanations, see Table 1 Missing data: variables ‘time to FNAC’ (classical Hodgkin lymphoma: OPs = 5, IPs = 3; large B-cell lymphoma:
OPs = 7, IPs = 5), ‘time to excisional biopsy’ (classical Hodgkin lymphoma: OPs = 0, IPs = 1; large B-cell lymphoma: OPs = 3, IPs = 1), ‘B symptoms’ (classical Hodgkin
lymphoma: OPs = 2, IPs = 1; large B-cell lymphoma: OPs = 4, IPs = 3)
Bosch et al. BMC Cancer  (2018) 18:276 Page 8 of 15
Table 4 Characteristics of follicular and mature nodal peripheral T-cell lymphomas in outpatient and inpatient cohorts
Follicular lymphoma (N = 562) Nodal peripheral T-cell lymphoma (N = 261)
Characteristic OPs 1 (n = 439) IP 2 (n = 123) P value 1 vs 2 OPs 1 (n = 160) IP 2 (n = 101) P value 1 vs 2
Age (years), mean (SD) 61.1 (18.4) 65.6 (13.6) <.001 62.1 (14.3) 68.5 (12.4) <.001
≤ 60, n (%) 212 (48.3) 40 (32.5) <.001 75 (46.9) 21 (20.8) <.001
> 60, n (%) 227 (51.7) 83 (67.5) <.001 85 (53.1) 80 (79.2) <.001
Sex, n (%)
Females 224 (51.0) 59 (48.0) .071 67 (41.9) 38 (37.6) .066
Males 215 (49.0) 64 (52.0) .074 93 (58.1) 63 (62.4) .068
Clinical manifestations, n (%)
Lymphadenopathy 356 (81.1) 82 (66.7) <.001 91 (56.9) 39 (38.6) <.001
Systemic symptoms 52 (11.8) 19 (15.4) .058 54 (33.8) 47 (46.5) <.001
Pain symptoms 13 (3.0) 9 (7.3) .037 10 (6.3) 13 (12.9) <.001
Chest symptoms 12 (2.7) 8 (6.5) .054 3 (1.9) 1 (1.0) .211
Other symptoms/signs 6 (1.4) 5 (4.1) .086 2 (1.3) 1 (1.0) .235
Successive/first visit ratio 2.10 2.66
QDU time for diagnosis /admission time for
diagnosis (days), mean (SD)
15.8 (1.8) 11.5 (2.3) .002 18.3 (2.4) 14.9 (3.0) .007
Suspected/compatible lymphoma by
FNAC, n (%)/total n
230 (68.5)/336 33 (70.2)/47 .143 45 (58.4)/77 19 (57.6)/33 .215
Time to FNAC (days), mean (SD) 1.4 (0.7) 1.3 (0.5) .120 1.1 (0.6) 1.2 (0.4) .184
Time to excisional biopsy (days), mean (SD) 7.6 (1.5) 3.8 (1.0) .006 7.2 (1.3) 2.9 (0.8) <.001
ECOG performance score > 1, n (%)/total n 24 (5.7)/418 12 (10.4)/115 .031 48 (31.6)/152 37 (37.8)/98 .020
B symptoms, n (%) 61 (13.9) 24 (19.5) .020 90 (56.3) 64 (63.4) <.001
Serum LDH > UNL, n (%) 92 (21.0) 34 (27.6) .003 96 (60.0) 69 (68.3) <.001
Extranodal disease, n (%) 38 (8.7) 14 (11.4) .093
> 1 extranodal site, n (%) 63 (39.4) 52 (51.5) <.001
Histologic grading, n (%)
1 123 (28.0) 33 (26.8) .157
2 172 (39.2) 48 (39.0) .208
3A 114 (26.0) 36 (29.3) .063
Unspecified 30 (6.8) 6 (4.9) .135
Ann Arbor stage, n (%)
I-II 156 (35.5) 38 (30.9) .033 36 (22.5) 14 (13.9) <.001
III-IV 283 (64.5) 85 (69.1) .034 124 (77.5) 87 (86.1) <.001
FLIPI score, n (%)/total n
Low risk (0-1) 165 (37.6)/439 41 (33.3)/123 .040
Intermediate risk (2) 153 (34.9)/439 43 (35.0)/123 .214
High risk (3-5) 121 (27.6)/439 39 (31.7)/123 .049
IPI score, n (%)/total n
Low risk (0-1) 30 (19.7)/152 13 (13.3)/98 .008
Intermediate risk (2-3) 75 (49.3)/152 47 (48.0)/98 .179
High risk (4-5) 47 (30.9)/152 38 (38.8)/98 <.001
Abbreviations: FLIPI follicular lymphoma international prognostic index
For other abbreviations, definitions, and explanations, see Tables 1 and 3
Missing data: variables ‘time to FNAC’ (follicular lymphoma: OPs = 8, IPs = 5; nodal peripheral T-cell lymphoma: OPs = 4, IPs = 3), ‘time to excisional biopsy’ (follicular
lymphoma: OPs = 2, IPs = 2; nodal peripheral T-cell lymphoma: OPs = 1, IPs = 0), ‘B symptoms’ (follicular lymphoma: OPs = 2, IPs = 0; nodal peripheral T-cell lymphoma:
OPs = 3, IPs = 2)
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more likely than outpatients to have high-risk prognos-
tic scores. Lastly, in all subtypes, there was a minimal
rate (≤ 4.1%) of missing data on the variables time to
FNAC, time to excisional biopsy, and B symptoms (see
footnotes of Tables 3 and 4).
Frequency and characteristics of lymphomas according to
referral sources
Potential differences between lymphoma subtypes and
their main characteristics between outpatients and inpa-
tients were determined according to the referral sources
(Table 5). Outpatients referred from ED were more com-
monly diagnosed with large B-cell and nodal peripheral
T-cell lymphomas than those referred from PC. In con-
trast, classical Hodgkin and follicular lymphomas were
more common among outpatients referred from PC.
Moreover, outpatients referred from ED were more
likely than those referred from PC to have an age >
60 years, a higher frequency of systemic and B symp-
toms, a worse performance status, and an increased
LDH. Also, a III/IV Ann Arbor stage was slightly more
common in outpatients referred from ED than from PC,
yet without statistically significant differences. Regarding
inpatients, those referred from ED were more often
diagnosed with large B-cell and nodal peripheral T-cell
lymphomas than those referred from PC. In contrast,
classical Hodgkin and follicular lymphomas were a more
common diagnosis in inpatients referred from PC. Inpa-
tients referred from ED were also more likely than those
referred from PC to have an increased LDH. Although
the former had a higher frequency of systemic and B
symptoms, a worse performance status, and a more
advanced Ann Arbor stage than the latter, differences
did not reach statistical significance (Table 5).
Results of cost analysis
Table 6 shows the mean costs per day of hospitalization
for diagnosis, per outpatient visit, and per patient in
inpatients and outpatients. Considering that the mean
admission time for diagnosis of inpatients was 12.3 (3.3)
days and that the mean number of visits of outpatients
(corresponding to the mean QDU time for diagnosis)
was 3.26 (1.2), the total cost per hospitalized patient was
€4039.56 (513.02), with 69.5% being attributable to
personnel salaries and 25.4% to diagnostic tests, and the
total cost per outpatient was €1408.48 (197.32), with
50.6% being attributable to diagnostic tests, 29.5% to out-
patient visits, and 18.6% to personnel salaries. According
to the analysis, the total saving from hospitalization was
€2631.08 per patient. There was some degree of missing
data on the variables diagnostic tests, therapeutic proce-
dures, pharmaceuticals and consumables, and consulta-
tions (see footnote of Table 6).
Discussion
This study revealed that, following referral to hospital,
diagnosis of lymphoma is more rapidly accomplished by
conventional hospitalization than by hospital-based am-
bulatory quick diagnostic clinics. Yet the outpatient ap-
proach appears to be cost-effective and not detrimental.
While no previous study has reported the time to diag-
nosis and associated costs of an outpatient vs inpatient
Table 5 Frequency and main characteristics of lymphoma subtypes in outpatient and inpatient cohorts according to referral sources
OPs (N = 1184) IPs (N = 535)
PC (n = 894) ED (n = 290) P value PC (n = 169) ED (n = 366) P value
Classical Hodgkin lymphoma, n (%) 183 (20.5) 33 (11.3) <.001 41 (24.3) 61 (16.7) <.001
Large B-cell lymphoma, n (%) 242 (27.1) 127 (43.8) <.001 54 (32.0) 155 (42.3) <.001
Follicular lymphoma, n (%) 370 (41.4) 69 (23.8) <.001 50 (29.6) 73 (19.9) <.001
Nodal peripheral T-cell lymphoma, n (%) 106 (11.9) 54 (18.6) <.001 24 (14.2) 77 (21.0) <.001
Age > 60 years, n (%) 451 (50.4) 160 (55.2) <.001 123 (72.8) 260 (71.0) .108
ECOG performance score > 1, n (%) 120 (13.4) 53 (18.3) <.001 36 (21.3) 87 (23.8) .089
B symptoms, n (%) 244 (27.3) 93 (32.1) .001 61 (36.1) 143 (39.1) .052
Systemic symptoms, n (%) 186 (20.8) 72 (24.8) .012 57 (33.7) 134 (36.6) .060
Pain symptoms, n (%) 33 (3.7) 10 (3.4) .197 14 (8.3) 32 (8.7) .210
Serum LDH > UNL, n (%) 287 (32.1) 115 (39.7) <.001 68 (40.2) 172 (47.0) <.001
Ann Arbor III/IV stage, n (%) 520 (58.2) 173 (59.7) .103 108 (63.9) 244 (66.7) .066
High risk IPI score (LBCL), n (%) 42 (17.4) 22 (17.3) .230 13 (24.1) 36 (23.2) .167
High risk IPI score (NPTCL), n (%) 32 (30.2) 15 (27.8) .081 9 (37.5) 29 (37.7) .231
High risk FLIPI score, n (%) 101 (27.3) 20 (29.0) .098 16 (32.0) 23 (31.5) .195
High risk IPS score, n (%) 25 (13.7) 5 (15.2) .106 8 (19.5) 12 (19.7) .252
Abbreviations: PC primary care; ED emergency department; LBCL large B-cell lymphoma; NPTCL nodal peripheral T-cell lymphoma
For other abbreviations, definitions, and explanations, see Tables 1, 3, and 4
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setting in patients with lymphoma, our study is the first
to explicitly describe the clinical and prognostic features
of major subtypes of lymphoma according to an out-
patient or inpatient diagnosis.
The general features of each lymphoma subtype were
consistent with well-known distinctive features. How-
ever, there were salient differences between the inpatient
and outpatient cohorts. First, lymphoma subtypes in
inpatients were more aggressive than in outpatients.
Second, inpatients were significantly older and less likely
to have lymphadenopathy but more likely in general to
have systemic and pain symptoms, worse performance
status, advanced Ann Arbor stages, B symptoms, in-
creased LDH, bulky disease, extranodal disease, and high-
risk prognostic scores than outpatients. It was of note that
the admission time for diagnosis of inpatients was signifi-
cantly shorter than the QDU time for diagnosis of outpa-
tients. However, because the management of patients
referred to outpatient clinics or admitted for investigation
of clinical manifestations such as to those reported here
and who have an eventual diagnosis of lymphoma can be
different in other settings, a circumstance that may
depend on various factors such as the type of hospital, the
available resources, or the institution traditions, the ap-
plicability of the study findings outside Spain is limited,
which is an intrinsic limitation. Similarly, although oncol-
ogists and hematopathologists - including those from the
US - agree that histopathology is essential in lymphoma to
make therapeutic decisions [31], excisional biopsy in the
US is done much less frequently than in our study (i.e. it
is usually performed only after FNAC and only if the diag-
nosis cannot be reached). Indeed, excisional biopsy is a
requirement of the hematology (for QDU (1) outpatients)
and the oncology (for QDU (2) outpatients) departments.
Therefore, our findings about FNAC/biopsy diagnosis of
lymphoma may not be generalizable either.
Although the role of FNAC in the diagnosis of lymphoma
is highly controversial [40], several investigators support it
as a first, time-saving route for patients with a clinical
suspicion of malignancy [41–44], mainly to differentiate
metastatic solid cancer from lymphoma lymphadenopathy.
In these cases, however, the operator experience in
obtaining adequate fine needle aspirates for cytomor-
phology, flow cytometry, and immunocytochemistry
studies is essential [42].
Undeniably, evaluating lymphomas by means of FNAC
is challenging. Limitations include sampling error, scarce
material to effectively perform flow cytometry and further
studies, a relatively high rate of false-negative results, and
loss of architecture [9, 40, 42, 45–47]. Nevertheless, it can
be a reliable procedure when samples are handled by
skilled cytopathologists assisted by specialists in flow
cytometry/immunocytochemistry [36, 42].
A former study in 372 consecutive patients referred to
QDU (1) for evaluation of peripheral lymphadenopathy
revealed malignancy in 120 (32.3%), with an initial fast
FNAC being highly specific and sensitive for the diagno-
sis of metastatic disease. Also, while all patients with
lymphoma were fully subtyped by biopsy, a suspicious/
compatible diagnosis was initially reached by combining
Table 6 Mean costs (€) of outpatients (n = 1184) and inpatients (n = 535)
Items Inpatients Outpatients Cost per patient (€), mean (SD)
One-day stay One visit Inpatientsa Outpatientsb P value
Staff salaryc 228.17d 80.52 2806.49 (174.00) 262.50 (22.92) <.001
QDU (1) and (2) visitse na 127.24 na 414.80 (0.11)
Diagnostic testsf 83.48 218.77 1026.80 (76.00) 713.19 (38.85) <.001
Therapeutic proceduresg 1.67 0.54 20.54 (3.53) 1.76 (0.23) <.001
Pharmaceuticals and consumables 9.95 0.87 122.39 (20.44) 2.84 (0.59) <.001
Consultationsh 2.47 0.32 30.38 (9.57) 1.04 (0.37) <.001
Adverse events 0.50 0.09 6.15 (2.37) 0.29 (0.10) <.001
Depreciation 2.18 3.70 26.81 (2.44) 12.06 (0.90) <.001
Total costs 328.42 432.05 4039.56 (513.02) 1408.48 (197.32) <.001
Abbreviations: na not applicable. For other abbreviations, see Table 1
aMean (SD) overall admission time for diagnosis: 12.3 (3.3) days
bMean (SD) overall number of outpatients’ visits during the QDU time for diagnosis: 3.26 (1.2)
cSee Methods for details about salary of staff at inpatient wards
dSalary of staff at inpatient wards in charge of 12.5 patients (each ward has 25 beds)
eThe cost of an average outpatient consultation was based on officially established Catalan Health Service fees
fInclude costs of laboratory testing and any other investigation (e.g. imaging studies or cytologies and biopsies). The costs of each type of diagnostic tests were
based on hospital tariffs in QDU (1) and established fees of the Catalan Health Service in QDU (2)
gInclude costs of procedures such as therapeutic paracentesis and thoracentesis performed to drain excessive amounts of ascites and pleural fluid, respectively
hInclude costs of consultations with professionals such as hospital specialists, dieticians, and social workers
Missing data: variables ‘diagnostic tests’ (outpatients = 2.2%, inpatients = 1.5%)¸ ‘therapeutic procedures’ (inpatients = 0.2%)¸ ‘pharmaceuticals and consumables’
(outpatients = 1.7%, inpatients = 1.6%), ‘consultations’ (outpatients = 9.4%, inpatients = 6.8%)
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cytomorphology and flow cytometry results in over two-
thirds of cases. Owing to insufficient material for flow
cytometry or cytomorphology in several cases and the
need to perform an excisional biopsy as the unique
diagnostic approach, time to diagnosis was significantly
longer in lymphoma than in metastatic lymphadenop-
athy [36]. These findings led us to conclude that a quick
FNAC rather than a conventional biopsy can be safely
recommended as the initial procedure in patients with
suspicious malignant lumps, mostly to differentiate me-
tastasis from lymphomas [36]. In fact, our QDU policy
establishes that, if metastatic solid cancer is undisputable
by FNAC, an immediate referral to the oncologist will
be time-saving, preferably after ordering an imaging
examination to locate the primary tumor site if not
ostensible before referral. At the first oncologist appoint-
ment, they may still order further histological studies for
molecular characterization, complete the staging, and
decide the best treatment for the patient. Alternatively,
if a clearly suspicious/compatible diagnosis of lymphoma
is beyond any doubt by FNAC, an immediate referral to
the hematologist will also be time-saving, ever ensuring
that an excisional biopsy (and ideally a PET-CT scan) has
been ordered and scheduled after personal communica-
tion with the relevant surgeon. At the first hematologist
appointment, the biopsy report will hopefully be ready to
read and review and the specialist will likely complete the
staging, including a bone marrow biopsy if needed, and
decide the best treatment.
Although depending on its subtype, biology and aggres-
siveness, a delay to diagnosis always constitutes a major
concern in lymphomas [48]. The diagnostic interval in
secondary care can exceed not only the PC interval but
even outdo the treatment interval (i.e. from diagnosis to
first treatment) [2]. As a matter of example, a distinct re-
ferral pathway for patients referred for lymph node biopsy
is frequently lacking in hospital centers [3]. Thus, whereas
lymphoma patients most commonly present with periph-
eral lymphadenopathy - otherwise the strongest predictor
of non-Hodgkin and Hodgkin lymphoma in patients
aged ≥40 years in PC [1, 10, 48] - service delivery for
peripheral lymphadenopathy has been reported to be
poorly rationalized [49, 50]. An interesting study con-
ducted in a UK hospital in patients with peripheral
lymphadenopathy referred for excisional biopsy re-
vealed that waiting times to it were significantly differ-
ent according to the referral method [51]. Specifically,
patients referred from several sources (mainly the
hematology department and general practice) waited a
median of 51 days before biopsy when referral was made
by post compared to 17 days for faxed referrals and just
4 days when referral was made by direct personal request.
A surgical outpatient appointment for routine surgical
assessment prior to biopsy was the norm for patients
referred by letter, whereas those referred following per-
sonal request proceeded straight to biopsy. After this
study, and with 43% of biopsies revealing malignancy, the
authors’ hospital implemented a fast-track, direct-booking
pathway to arrange day-case lymph node biopsies without
prior discussion with a surgeon [51].
In our study, 68.4% of inpatients vs 24.5% of outpa-
tients with lymphomas were diagnosed via emergency
admission. Because inpatients have preferential access to
investigations, PC physicians commonly refer patients
with potentially serious conditions directly to the ED in
the hope of gaining rapid, including invasive, diagnostic
procedures [12, 14]. Disturbingly, some patients referred
from PC to the ED are in turn referred from ED to
QDU (1) both in this study (data not shown) and in
others [11]. Referring patients with suspected malig-
nancy, including lymphoma, to the ED to achieve a
quicker access to investigations is not uncommon in
countries other than Spain including, among others, the
United States (US) [52, 53].
In the UK, during 2006-2013, approximately 27 and
17% of all patients with non-Hodgkin and Hodgkin
lymphoma, respectively, were diagnosed after ED pres-
entation [54, 55]. While the survival rates of these
patients were significantly lower than those observed in
all other routes to diagnosis, the proportion of ED pre-
sentations increased with increasing age. Thus, the sur-
vival differences were partly explained by the higher
proportion of ED presentations among older individuals,
as has also been observed in several major types of solid
cancer [56]. Although outcomes and survival rates were
not investigated in the current study, outpatients and
inpatients diagnosed after ED presentation had more
aggressive lymphomas, with outpatients referred from
ED being older than those referred from PC.
Finally, despite the differences in the time to diagnosis,
the remarkable cost differences of the diagnostic evalu-
ation were of note and agreed with findings in studies
comparing the costs incurred by QDUs vs admission for
disorders such as severe anemia, fever of unknown origin,
or lung cancer [12, 13, 25]. A recent cost-minimization
study in 63 patients with lymphomas diagnosed at
QDU (2) revealed a total cost per hospitalized patient
of €5457.42 and of €976.01 per outpatient, meaning a
total saving from hospitalization of €4481.41 per pa-
tient, or €282,328.83 for the overall sample [25]. Al-
though economic evaluation studies of QDUs are
scarce [11–13, 15, 25, 26], savings from hospitalization
are overwhelmingly associated with health personnel
wages when considering the fractions corresponding
to the hours worked.
Strengths of our study included the large sample of
patients (N = 1779), its duration (10 years), and a design
that allowed to analyze representative samples of major
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lymphoma subtypes according to their aggressive or in-
dolent clinical behavior. Nonetheless, our study should
be interpreted in the context of its limitations such as
those mentioned above. In addition, and despite the
finding of significant savings from hospitalization, there
may be multiple factors involved in inpatient admission
which were not accounted for in the cost analysis. For
instance, aggressive lymphomas are a complex disorder
which often require admission for diagnosis due to
lymphoma causing severe clinical manifestations other
than those described here and that may not be ad-
equately managed in an outpatient unit that is open for
5 h 4 days a week and markedly less staffed. In brief,
diagnosis in the hospital may be worth the cost if there
are other competing or complementary diagnoses that
are managed or treated at the same time. Although
detailed clinical, histopathological and cytological infor-
mation of all inpatients and outpatients were carefully
reviewed, certain relevant details might not have been
completely captured and potential confounders were not
measured - a limitation related to the retrospective design
of the study. Furthermore, waiting times to treatment and
outcomes were not analyzed, meaning potential differ-
ences between cohorts could not be analyzed either.
Finally, even though QDUs seem more appropriate for
countries with public health care systems, it should be
remarked that inpatient admissions in the US - where the
health care system is mainly owned by the private sector -
also constitute a major component of health costs [57]. A
systematic review of Spanish QDUs by US investigators
concluded that “[in] our healthcare system with the high
cost of inpatient care, the QDU can yield large savings of
healthcare dollars while expediting diagnostic workup,
increasing patient satisfaction, and preventing lost
productivity from hospital stays” [16]. Although some
outpatient care is provided by US hospitals in their EDs
and specialty clinics, hospitals primarily exist in this
country to provide inpatient care. Moreover, ED physi-
cians commonly hospitalize patients for workup [16, 58].
Conclusion
In summary, among 1779 patients diagnosed with four
major subtypes of lymphomas during a 10-year period
after referral to hospital-based outpatient diagnostic
clinics or hospitalized, clinically aggressive subtypes in-
cluding large B-cell and nodal peripheral T-cell lymph-
omas prevailed in admitted patients. For each lymphoma
subtype, inpatients were older, had a higher frequency of
systemic symptoms than outpatients, and were generally
more likely to have a worse performance status, a more
advanced Ann Arbor stage, and a higher frequency of B
symptoms, increased LDH, bulky disease, extranodal
disease, and high-risk prognostic scores. Regardless of
the clinical setting, patients referred from EDs had more
aggressive lymphoma subtypes than those referred from
PCs. Of note, the time to histopathological diagnosis of
patients hospitalized for workup was significantly shorter
than that of patients evaluated at QDU. Lastly, although
there were considerable cost differences between the
two settings, there may be other issues associated with ad-
mission which may not be properly and safely managed or
treated in an outpatient environment and the cost analysis
did not account for this potentially added value.
Since outcomes of outpatients and inpatients were not
investigated in our study, a challenge of a potential future
research is to analyze the impact on outcome of an out-
patient vs inpatient diagnostic setting in these patients.
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